Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

29.76
+1.374.83%
Post-market: 29.810.0542+0.18%19:56 EDT
Volume:2.46M
Turnover:72.85M
Market Cap:3.07B
PE:-35.53
High:30.50
Open:28.74
Low:28.61
Close:28.39
52wk High:38.26
52wk Low:16.02
Shares:103.29M
Float Shares:91.60M
Volume Ratio:1.31
T/O Rate:2.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8376
EPS(LYR):-0.8100
ROE:-8.18%
ROA:-17.01%
PB:2.88
PE(LYR):-36.74

Loading ...

Beam Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 18

JonesTrading Sticks to Its Buy Rating for Beam Therapeutics (BEAM)

TIPRANKS
·
Apr 07

Why Beam Therapeutics (BEAM) Is Up 12.6% After NEJM Base-Editing Sickle Cell Data Publication

Simply Wall St.
·
Apr 06

Beam Therapeutics CEO John M. Evans disposes of $1.1 million common shares

Reuters
·
Apr 02

Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial

TIPRANKS
·
Apr 02

Beam risto-cel BEACON trial data in NEJM support BLA filing by late 2026

Reuters
·
Apr 02

Beam Therapeutics (BEAM) Gets a Buy from Wedbush

TIPRANKS
·
Mar 28

Beam Therapeutics (BEAM) Gets a Buy from Bernstein

TIPRANKS
·
Mar 26

BUZZ-U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings

Reuters
·
Mar 26

Clear Street sees buying opportunity for Beam Therapeutics after study update

TIPRANKS
·
Mar 26

Beam Therapeutics: BEAM-302’s Differentiated AATD Profile and Accelerated Path Support Buy Rating and $80 Target

TIPRANKS
·
Mar 25

A Look At Beam Therapeutics (BEAM) Valuation After Positive BEAM 302 Data And Accelerated Approval Plans

Simply Wall St.
·
Mar 25

BUZZ-U.S. STOCKS ON THE MOVE-Arm, Destiny Tech100, Terns Pharma

Reuters
·
Mar 25

BUZZ-Beam Therapeutics rises after gene-editing drug shows promise in rare lung and liver disease

Reuters
·
Mar 25

Beam Therapeutics Shares up 14% Premarket After Co's Gene‑Editing Drug Showed Promising Results in Trial for Rare Lung and Liver Disease

THOMSON REUTERS
·
Mar 25

Beam Therapeutics selects 60 mg BEAM-302 for pivotal development; Phase 1/2 trial mean steady-state total AAT climbs to 16.1 µM at 60 mg

Reuters
·
Mar 25

Beam Therapeutics Inc: Global Pivotal Cohort Expected to Initiate in Second Half of 2026

THOMSON REUTERS
·
Mar 25

Beam Therapeutics: Corrected M-Aat Comprised 94% of Total Aat With a Concomitant 84% Reduction in Mutant Z-Aat Following Beam-302 60 Mg Treatment

THOMSON REUTERS
·
Mar 25

Beam Therapeutics Inc: 60 Mg Selected as Optimal Biological Dose, Supported by Strong Safety and Efficacy Profile Across Single-Dose Cohorts

THOMSON REUTERS
·
Mar 25

Hitachi Cooling & Heating Supports Hong Kong's Net-Zero Transition with BEAM Plus-Aligned VRF Solutions

prnewswire
·
Mar 23